Rese-Cel CAR T Therapy Secures EMA PRIME Designation

 
• By Neena Brizmohun
  
Inflammatory myopathy written on a board
A CAR T-cell therapy for idiopathic inflammatory myopathy has received EMA PRIME designation (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Review Pathways

More from Europe